← All trials
NCT02166424
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 1, 2014
- Primary completion
- Sep 1, 2017
- Completion date
- Dec 1, 2017
- First posted
- —
- Last posted
- —
- Enrollment
- 108
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Tokyo Medical UniversityLead sponsor
- Tokyo Medical UniversityOverall official - principal investigator
- Tokyo Medical UniversityReponsible party - principal investigator
- University of ToyamaCollaborator
- Chiba UniversityCollaborator
- Japan Society for the Promotion of ScienceCollaborator
- China Medical UniversityOverall official - principal investigator
- China Medical UniversityCollaborator
- National Center for Child Health and Development, JapanCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.